303 related articles for article (PubMed ID: 29429612)
21. Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels.
Santini V; Almeida A; Giagounidis A; Skikne B; Beach CL; Weaver J; Tu N; Fenaux P
Leuk Lymphoma; 2020 Jun; 61(6):1475-1483. PubMed ID: 32064987
[TBL] [Abstract][Full Text] [Related]
22. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
23. Health-related quality of life outcomes of lenalidomide in transfusion-dependent patients with Low- or Intermediate-1-risk myelodysplastic syndromes with a chromosome 5q deletion: results from a randomized clinical trial.
Revicki DA; Brandenburg NA; Muus P; Yu R; Knight R; Fenaux P
Leuk Res; 2013 Mar; 37(3):259-65. PubMed ID: 23273538
[TBL] [Abstract][Full Text] [Related]
24. Azacitidine in Lower-Risk Myelodysplastic Syndromes: A Meta-Analysis of Data from Prospective Studies.
Komrokji R; Swern AS; Grinblatt D; Lyons RM; Tobiasson M; Silverman LR; Sayar H; Vij R; Fliss A; Tu N; Sugrue MM
Oncologist; 2018 Feb; 23(2):159-170. PubMed ID: 29118268
[TBL] [Abstract][Full Text] [Related]
25. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
26. Impact of Lenalidomide Treatment on Overall Survival in Patients With Lower-Risk, Transfusion-Dependent Myelodysplastic Syndromes.
Santini V; Giagounidis A; Pelligra CG; Franco-Villalobos C; Tang D; Morison J; Beach CL; Hu A; Platzbecker U; Fenaux P
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e874-e883. PubMed ID: 35710702
[TBL] [Abstract][Full Text] [Related]
27. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes.
Sekeres MA; Maciejewski JP; Giagounidis AA; Wride K; Knight R; Raza A; List AF
J Clin Oncol; 2008 Dec; 26(36):5943-9. PubMed ID: 19018091
[TBL] [Abstract][Full Text] [Related]
28. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.
Fenaux P; Giagounidis A; Selleslag D; Beyne-Rauzy O; Mufti G; Mittelman M; Muus P; Te Boekhorst P; Sanz G; Del Cañizo C; Guerci-Bresler A; Nilsson L; Platzbecker U; Lübbert M; Quesnel B; Cazzola M; Ganser A; Bowen D; Schlegelberger B; Aul C; Knight R; Francis J; Fu T; Hellström-Lindberg E;
Blood; 2011 Oct; 118(14):3765-76. PubMed ID: 21753188
[TBL] [Abstract][Full Text] [Related]
29. Lenalidomide: targeted anemia therapy for myelodysplastic syndromes.
List AF; Baker AF; Green S; Bellamy W
Cancer Control; 2006 Dec; 13 Suppl():4-11. PubMed ID: 17242661
[TBL] [Abstract][Full Text] [Related]
30. Impact of lenalidomide use among non-transfusion dependent patients with myelodysplastic syndromes.
Brunner AM; Weng S; Cronin A; Fathi AT; Habib AR; Stone R; Graubert T; Steensma DP; Abel GA
Am J Hematol; 2018 Sep; 93(9):1119-1126. PubMed ID: 30033577
[TBL] [Abstract][Full Text] [Related]
31. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
32. Lenalidomide for myelodysplastic syndromes with del(5q): how long should it last?
Vozella F; Latagliata R; Carmosino I; Volpicelli P; Montagna C; Romano A; Roberto A; Finsinger P; Mancini M; Breccia M; Oliva E; Oliva E
Hematol Oncol; 2015 Mar; 33(1):48-51. PubMed ID: 25950027
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
[TBL] [Abstract][Full Text] [Related]
34. Lenalidomide in patients with red blood cell transfusion-dependent myelodysplastic syndrome and del(5q): a single-centre "real-world" experience.
Cerqui E; Pelizzari A; Schieppati F; Borlenghi E; Pagani C; Bellotti D; Lamorgese C; Boiocchi L; Sottini A; Imberti L; Rossi G
Leuk Lymphoma; 2015; 56(11):3129-34. PubMed ID: 25811676
[TBL] [Abstract][Full Text] [Related]
35. Transfusion dependence development and disease evolution in patients with MDS and del(5q) and without transfusion needs at diagnosis.
Rojas SM; Díez-Campelo M; Luño E; Cabrero M; Pedro C; Calabuig M; Nomdedeu B; Cedena T; Arrizabalaga B; García M; Cerveró C; Collado R; Azaceta G; Ardanaz MT; Muñoz JA; Xicoy B; Rodríguez MJ; Bargay J; Morell MJ; Simiele A; del Cañizo C
Leuk Res; 2014 Mar; 38(3):304-9. PubMed ID: 24333115
[TBL] [Abstract][Full Text] [Related]
36. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
[TBL] [Abstract][Full Text] [Related]
37. Lenalidomide treatment of Japanese patients with myelodysplastic syndromes with 5q deletion: a post-marketing surveillance study.
Uno S; Motegi Y; Minehata K; Aoki Y
Int J Hematol; 2023 Oct; 118(4):432-442. PubMed ID: 37493867
[TBL] [Abstract][Full Text] [Related]
38. Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS.
List AF; Bennett JM; Sekeres MA; Skikne B; Fu T; Shammo JM; Nimer SD; Knight RD; Giagounidis A;
Leukemia; 2014 May; 28(5):1033-40. PubMed ID: 24150217
[TBL] [Abstract][Full Text] [Related]
39. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
[TBL] [Abstract][Full Text] [Related]
40. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene.
Blommestein HM; Armstrong N; Ryder S; Deshpande S; Worthy G; Noake C; Riemsma R; Kleijnen J; Severens JL; Al MJ
Pharmacoeconomics; 2016 Jan; 34(1):23-31. PubMed ID: 26314282
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
